首页 > 市场调查报告书 > 製药

精神疾病

市场调查报告书

商品编码

1271206

躁郁症治疗市场，各药物类别，各流通管道，各地区-规模，占有率，展望，机会分析，2023年～2030年

Bipolar Disorder treatment Market, By Drug Class, By Distribution Channel, And by Region - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

出版日期: 2023年04月18日 | 出版商:

Coherent Market Insights | 英文 201 Pages | 商品交期: 2-3个工作天内

价格

简介目录

躁郁症是一种终生疾病，可以透过适当的药物治疗来控制。用于控制躁郁症症状的药物包括情绪稳定剂和非典型抗精神病药。锂与其他药物等情绪稳定剂透过抑制躁狂和抑郁等情绪波动来治疗躁郁症。患有躁郁症的人会经历异常强烈的情绪、不规律的睡眠模式、不规律的活动水准和情绪发作。躁郁症是根据患者的症状、家族史和生活史来诊断的。医疗保健提供者通常会进行心理健康评估以诊断躁郁症。

市场上主要参与者日益采用合併、协议和合作等无机成长战略，预计将推动预测期内的市场成长。

本报告对全球躁郁症治疗市场进行了深入分析，并提供了预测期(2023-2030年)的市场规模(百万美元)和年复合成长率(CAGR%)，以 2022年为基准年。

Takeda Pharmaceutical Company Limited
Pfizer, Inc.
Allergan plc.
Otsuka Holdings Co. Ltd.
Johnson & Johnson
Eli Lilly and Company
GlaxoSmithKline plc.
AstraZeneca Plc.
Novartis International AG
AbbVie Inc.
Lundbeck A/S
Minerva Neurosciences
Sumitomo Dainippon Pharma Co., Ltd.
Intra-Cellular Therapies Inc.
Gedeon Richter Plc.
Indivior PLC

第9章 Section

关于调查手法
关于出版社

简介目录

Product Code: CMI2605

Bipolar disorder is a lifelong disease, which can be managed with proper medication. The medications used to manage bipolar disorder symptoms include mood stabilizers and atypical antipsychotics. Mood stabilizers such as lithium and other drugs are used for the treatment of bipolar disorders by suppressing mood swings such as mania and depression. Cariprazine is an atypical antipsychotic drug indicated for the treatment of depressive episodes associated with bipolar I disorder in adults. Antidepressant medications are also prescribed to treat depressive episodes in bipolar disorder. Antidepressants combined with mood stabilizers are indicated to prevent the triggering of maniac episodes in patients with bipolar disorder. There is a sudden change in the mood of the patient and his/her ability to carry out daily tasks. There are four types of bipolar disorders: bipolar I, bipolar II, cyclothymic, and other specified and non-specified bipolar and related disorders. People suffering from bipolar disorder experience periods of unusually intense emotion, irregular sleep patterns, and activity levels, and mood episodes. Bipolar disorder is diagnosed based on the patient's symptoms, family history, and life history. The healthcare provider generally conducts a mental health evaluation for the diagnosis of bipolar disorder.

Market Dynamics

The increasing adoption of inorganic growth strategies such as mergers, agreements, and collaborations by key players operating in the market is expected to propel the market growth over the forecast period. For instance, in July 2019, Gedeon Richter plc, entered into an exclusive license agreement with Hikma Pharmaceuticals Plc. to commercialize cariprazine, a novel antipsychotic drug, in certain Middle East and North African or MENA markets. Moreover, earlier in August 2016, Gedeon RichterPlc. and Recordati signed an exclusive license agreement to commercialize cariprazine, a novel atypical antipsychotic drug in Western Europe, Algeria, and Tunisia.

Key features of the study:

This report provides in-depth analysis of the global bipolar disorder treatment market, and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global bipolar disorder treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study are Takeda Pharmaceutical Company Limited, Pfizer, Inc., Allergan plc, Otsuka Holdings Co. Ltd., Johnson & Johnson, Eli Lilly and Company, GlaxoSmithKline plc, AstraZeneca Plc, Novartis International AG, AbbVie Inc., H. Lundbeck A/S, Minerva Neurosciences, Sumitomo Dainippon Pharma Co., Ltd., Intra-Cellular Therapies Inc., Gedeon Richter Plc., and Indivior PLC
Insights from this report will allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global infection surveillance market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global bipolar disorder treatment market

Detailed Segmentation:

Global Bipolar Disorder Treatment Market, By Drug Class:
- Antipsychotics
- Antidepressants
- Mood Stabilizers
- Anti-anxiety Drugs and Others
Global Bipolar Disorder Treatment Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Bipolar Disorder Treatment Market, By Region:
- North America
  - By Country:
- U.S.
- Canada
- Latin America
  - By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
  - By Country:
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
  - By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
  - By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
  - By Country/Region:
- South Africa
- Central Africa
- North Africa
Company Profiles
- Takeda Pharmaceutical Company Limited*
  - Company Highlights
  - Products Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Pfizer, Inc.
- Allergan plc
- Otsuka Holdings Co. Ltd.
- Johnson & Johnson
- Eli Lilly and Company
- GlaxoSmithKline plc
- AstraZeneca Plc
- Novartis International AG
- AbbVie Inc.
- Lundbeck A/S
- Minerva Neurosciences
- Sumitomo Dainippon Pharma Co., Ltd.
- Intra-Cellular Therapies Inc.
- Gedeon Richter Plc.
- Indivior PLC

"*" marked represents similar segmentation in other categories in the respective section.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Key Highlights
Product Launch
Technological Advancements
PEST Analysis
Regulatory Scenario
Mergers and Acquisitions

4. Global Bipolar Disorder Treatment Market- Impact of Coronavirus (Covid-19) Pandemic

Economic Impact
COVID-19 Epidemiology
Impact on Supply and Demand

5. Global Bipolar Disorder Treatment Market, By Drug Class, 2017 - 2030, (US$ Million)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Antipsychotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Antidepressants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Mood Stabilizers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Anti-anxiety Drugs and Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

6. Global Bipolar Disorder Treatment Market, By Distribution Channel, 2017 - 2030, (US$ Million)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

7. Global Bipolar Disorder Treatment Market, By Region, 2017 - 2030, (US$ Million)

Introduction
- Market Share Analysis, By Region, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, For Regions, 2017-2030
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
U.S.
Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
North Africa
Central Africa
South Africa

8. Competitive Landscape

Takeda Pharmaceutical Company Limited *
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Pfizer, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Allergan plc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Otsuka Holdings Co. Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
GlaxoSmithKline plc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
AstraZeneca Plc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Novartis International AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
AbbVie Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Lundbeck A/S
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Minerva Neurosciences
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Sumitomo Dainippon Pharma Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Intra-Cellular Therapies Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Gedeon Richter Plc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Indivior PLC
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies

9. Section

Research Methodology
About Us

02-2729-4219

+886-2-2729-4219

License/价格

躁郁症治疗市场，各药物类别，各流通管道，各地区-规模，占有率，展望，机会分析，2023年～2030年

Bipolar Disorder treatment Market, By Drug Class, By Distribution Channel, And by Region - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

目录

第1章调查目的与前提条件

第2章市场展望

第3章市场动态，法规，趋势分析

第4章躁郁症治疗的全球市场冠状病毒(COVID-19)大流行造成的f的影响

第5章躁郁症治疗的全球市场，各药物类别，2017年～2030年

第6章躁郁症治疗的全球市场，各流通管道，2017年～2030年

第7章躁郁症治疗的全球市场:各地区，2017年～2030年

第8章竞争情形